Systemic chemotherapy in addition to CRS‐HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival-Reference-Cited by-同舟云学术

Systemic chemotherapy in addition to CRS‐HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival

Published:2024-09-11 Issue: Volume: Page:
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:Journal of Surgical Oncology

Author:

van den Heuvel Teun B. M.¹²,Lurvink Robin J.¹,Rovers Koen P. B.¹,van Hellemond Irene E. G.³,de Hingh Ignace H. J. T.¹²⁴^ORCID

Affiliation:

1. Department of Surgery Catharina Hospital Eindhoven Eindhoven The Netherlands

2. Department of Oncology and Developmental Biology (GROW), Faculty of Health, Medicine and Life Sciences Maastricht University Maastricht The Netherlands

3. Department of Medical Oncology Catharina Hospital Eindhoven Eindhoven The Netherlands

4. Department of Research & Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands

Abstract

AbstractIn patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery‐hyperthermic intraperitoneal chemotherapy (CRS‐HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6‐trial.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.27849

Reference28 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2021

2. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases;Geest LGM;Clin Exp Metastasis,2015

3. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population‐based study;Bakkers C;Ann Surg Oncol,2021

4. The impact of PRODIGE 7 on the current worldwide practice of CRS‐HIPEC for colorectal peritoneal metastases: a web‐based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI);Vlasakker VCJ;Eur J Surg Oncol,2021

5. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer;Verwaal VJ;J Clin Oncol,2003